Cardiovascular Revascularization Medicine
Volume 8, Issue 3 , Pages 183-188 , July 2007

Prolonged application of clopidogrel reduces inflammation after percutaneous coronary intervention in the porcine model

  • Yunus Ayral

      Affiliations

    • Department of Cardiology, Charité-Campus Benjamin Franklin, Berlin, Germany
    • ,
  • Ursula Rauch

      Affiliations

    • Department of Cardiology, Charité-Campus Benjamin Franklin, Berlin, Germany
    • Corresponding Author InformationCorresponding author. Medical Clinic of Cardiology and Pneumology, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, 12200 Berlin, Germany. Tel.: +49 30 8445 2362; fax: +49 30 8441 9991.
    • ,
  • Petra Goldin-Lang

      Affiliations

    • Department of Cardiology, Charité-Campus Benjamin Franklin, Berlin, Germany
    • ,
  • Caroline Stellbaum

      Affiliations

    • Department of Cardiology, Charité-Campus Benjamin Franklin, Berlin, Germany
    • ,
  • Carolin Deiner

      Affiliations

    • Department of Cardiology, Charité-Campus Benjamin Franklin, Berlin, Germany
    • ,
  • Peter L. Schwimmbeck

      Affiliations

    • Department of Cardiology, Klinikum Leverkusen, Leverkusen, Germany
    • ,
  • Heinz-Peter Schultheiss

      Affiliations

    • Department of Cardiology, Charité-Campus Benjamin Franklin, Berlin, Germany
    • ,
  • Klaus Pels

      Affiliations

    • Department of Cardiology, Charité-Campus Benjamin Franklin, Berlin, Germany

Received 29 November 2006 ,Revised 12 March 2007 ,Accepted 12 March 2007.

References 

  1. Berglund U, Richter A. Clopidogrel treatment before percutaneous coronary intervention reduces adverse cardiac events. J Invasive Cardiol. 2002;14(5):243–246
  2. Holmes DR. Antiplatelet therapy after percutaneous coronary intervention. Cerebrovasc Dis. 2006;21(Suppl 1):25–34
  3. Steinhubl SR, Berger PB, Mann JT, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288(19):2411–2420
  4. Chew DP, Bhatt DL, Robbins MA, et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88(6):672–674
  5. Klinkhardt U, Graff J, Harder S. Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Pharmacol Ther. 2002;71(3):176–185
  6. Yaron G, Brill A, Dashevsky O, et al. C-reactive protein promotes platelet adhesion to endothelial cells: a potential pathway in atherothrombosis. Br J Haematol. 2006;134(4):426–431
  7. Navarro Estrada JL, Gabay JM, Alvarez J, et al. Relation of C-reactive protein to extent and complexity of coronary narrowing in patients with non-ST elevation acute coronary syndromes. A prospective cohort study. Coron Artery Dis. 2004;15(8):477–484
  8. Giesen PL, Rauch U, Bohrmann B, et al. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci U S A. 1999;96(5):2311–2315
  9. Rauch U, Nemerson Y. Tissue factor, the blood, and the arterial wall. Trends Cardiovasc Med. 2000;10(4):139–143
  10. Carson SD, Johnson DR. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood. 1990;76(2):361–367
  11. Hamilton KK, Hattori R, Esmon CT, Sims PJ. Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J Biol Chem. 1990;265(7):3809–3814
  12. Kornowski R, Hong MK, Tio FO, Bramwell O, Wu H, Leon MB. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol. 1998;31(1):224–230
  13. Okamoto E, Couse T, De LH, et al. Perivascular inflammation after balloon angioplasty of porcine coronary arteries. Circulation. 2001;104(18):2228–2235
  14. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, et al. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J. 2000;21(14):1152–1158
  15. Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case–control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;144(6):537–547
  16. Schillinger M, Mlekusch W, Wolfram RM, et al. Endovascular brachytherapy: effect on acute inflammatory response after percutaneous femoropopliteal arterial interventions. Radiology. 2004;230(2):556–560
  17. Popma JJ, Suntharalingam M, Lansky AJ, et al. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation. 2002;106(9):1090–1096
  18. Waksman R, Raizner AE, Yeung AC, Lansky AJ, Vandertie L. Use of localised intracoronary beta radiation in treatment of in-stent restenosis: the INHIBIT randomised controlled trial. Lancet. 2002;359(9306):551–557
  19. Jaster M, Fuster V, Rosenthal P, et al. Catheter based intracoronary brachytherapy leads to increased platelet activation. Heart. 2004;90(2):160–164
  20. Liistro F, Falsini G, Angioli P, Ducci K, Bolognese L. Late acute thrombosis after implantation of sirolimus-eluting stent to treat in-stent restenosis. Acute Card Care. 2006;8(2):116–118
  21. Sambola A, Osende J, Hathcock J, et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation. 2003;107(7):973–977
  22. Versaci F, Gaspardone A, Tomai F, et al. Immunosuppressive Therapy for the Prevention of Restenosis After Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol. 2002;40(11):1935–1942
  23. Gaspardone A, Crea F, Versaci F, et al. Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. Am J Cardiol. 1998;82(4):515–518
  24. Zebrack JS, Anderson JL, Maycock CA, Horne BD, Bair TL, Muhlestein JB. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002;89(2):145–149
  25. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–533
  26. Waksman R, Ajani AE, Pinnow E, et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS4. Circulation. 2002;106(7):776–778
  27. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation. 2004;109(6):701–705
  28. Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the “real world”: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109(2):190–195
  29. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126–2130
  30. Finkelstein A, Hausleiter J, Doherty T, et al. Intracoronary beta-irradiation enhances balloon-injury-induced tissue factor expression in the porcine injury model. Int J Cardiovasc Intervent. 2004;6(1):20–27

☆ This work was supported by grants from the German Research Foundation [Sonderforschungsbereich Transregio 19 (SFB TR 19) to U.R. and to H.P.S. and Ra 799/3-1 to U.R. and K.P.].

PII: S1553-8389(07)00048-6

doi: 10.1016/j.carrev.2007.03.003

Cardiovascular Revascularization Medicine
Volume 8, Issue 3 , Pages 183-188 , July 2007

Article Tools

* Image Usage & Resolution